Liver Cancer  >>  carotuximab IV (ENV-105)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carotuximab IV (ENV-105) / Kairos Pharma
NCT01375569: TRC105 for Liver Cancer That Has Not Responded to Sorafenib

Completed
2
11
US
TRC105
National Cancer Institute (NCI)
Hepatocellular Carcinoma, Hepatocellular Cancer, Carcinoma, Hepatocellular
02/14
12/15
NCT01306058: Sorafenib and TRC105 in Hepatocellular Cancer

Checkmark Mature data in combination with TRC105 in HCC at ASCO GI 2019
Jan 2019 - Jan 2019: Mature data in combination with TRC105 in HCC at ASCO GI 2019
Checkmark In combination with TRC105 for hepatocellular cancer at ASCO 2015
May 2015 - Jun 2015: In combination with TRC105 for hepatocellular cancer at ASCO 2015
Checkmark ASCO 2015
More
Completed
1/2
27
US
TRC 105, Sorafenib, Nexavar
National Cancer Institute (NCI)
Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, Carcinoma, Hepatocellular, Liver Neoplasms, Experimental
06/16
06/17

Download Options